Use of proton pump inhibitors and mortality after hip fracture in a nationwide study
暂无分享,去创建一个
J. Zwerina | H. Dimai | K. Klaushofer | E. Zwettler | B. Reichardt | W. Brozek | B. Reichardt | J. Zwerina | H. Dimai | Klaus Klaushofer
[1] R. Trickett,et al. Prophylactic proton pump inhibitors in femoral neck fracture patients - A life - and cost-saving intervention. , 2016, Annals of the Royal College of Surgeons of England.
[2] P. Nasiri,et al. Correlation of Bone Mineral Density Scores and Proton Pump Inhibitors Use in the Elderly. , 2016, Current rheumatology reviews.
[3] S. Corrao,et al. Gender difference in drug use in hospitalized elderly patients. , 2015, European journal of internal medicine.
[4] J. Zwerina,et al. Mortality After Hip Fracture in Austria 2008–2011 , 2014, Calcified Tissue International.
[5] J. Zwerina,et al. Mortality After Hip Fracture in Austria 2008–2011 , 2014, Calcified Tissue International.
[6] C. Cooper,et al. The impact of common co-morbidities (as measured using the Charlson index) on hip fracture risk in elderly men: a population-based cohort study , 2014, Osteoporosis International.
[7] E. Kuipers,et al. A Benefit–Risk Assessment of the Use of Proton Pump Inhibitors in the Elderly , 2014, Drugs & Aging.
[8] E. di Giulio,et al. Proton pump inhibitor therapy and potential long-term harm , 2014, Current opinion in endocrinology, diabetes, and obesity.
[9] Wei Zhao,et al. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. , 2013, JAMA.
[10] S. Bandinelli,et al. Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals. , 2013, Bone.
[11] C. Cooper,et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden , 2013, Archives of Osteoporosis.
[12] B. Iglseder,et al. Stress ulcer prophylaxis, thromboprophylaxis and coagulation management in patients with hip fractures , 2013, Wiener Medizinische Wochenschrift.
[13] P. Emery,et al. Nonsteroidal Anti-Inflammatory Drugs, Gastroprotection, and Benefit–Risk , 2013, Pain practice : the official journal of World Institute of Pain.
[14] S. Wilhelm,et al. Perils and pitfalls of long-term effects of proton pump inhibitors , 2013, Expert review of clinical pharmacology.
[15] H. Song,et al. A population-based case–control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate , 2013, Journal of Gastroenterology.
[16] N. Vakil. Prescribing Proton Pump Inhibitors , 2012, Drugs.
[17] Alicia R. Desilets,et al. Considerations for the use of proton-pump inhibitors in older adults. , 2012, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.
[18] Xin-ji Zhang,et al. Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis , 2011, European journal of gastroenterology & hepatology.
[19] G. Leontiadis,et al. Proton Pump Inhibitors and Risk of Fracture: A Systematic Review and Meta-Analysis of Observational Studies , 2011, The American Journal of Gastroenterology.
[20] R. Eastell,et al. Proton pump inhibitor use and the antifracture efficacy of alendronate. , 2011, Archives of internal medicine.
[21] D. Bauer,et al. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. , 2011, The American journal of medicine.
[22] D. Metz,et al. Systematic Review of the Epidemiology of Complicated Peptic Ulcer Disease: Incidence, Recurrence, Risk Factors and Mortality , 2011, Digestion.
[23] Y. Loke,et al. Meta-analysis: risk of fractures with acid-suppressing medication. , 2011, Bone.
[24] C. Meier,et al. Proton Pump Inhibitors and Fracture Risk , 2010, Drug safety.
[25] J. Inadomi,et al. Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. , 2010, The American journal of managed care.
[26] C. Cooper,et al. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study , 2010, Osteoporosis International.
[27] M. Howell,et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. , 2010, Archives of internal medicine.
[28] Cathleen S. Colón-Emeric,et al. Meta-analysis: Excess Mortality After Hip Fracture Among Older Women and Men , 2010, Annals of Internal Medicine.
[29] Eve Donnelly,et al. The assessment of fracture risk. , 2010, The Journal of bone and joint surgery. American volume.
[30] S. Boonen,et al. Potential mediators of the mortality reduction with zoledronic acid after hip fracture , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[31] A. Pilotto,et al. Acid-related disorders in the elderly. , 2009, Best practice & research. Clinical gastroenterology.
[32] Michael D Howell,et al. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. , 2009, JAMA.
[33] D. Bauer,et al. Acid-Suppressive Medications and Risk of Bone Loss and Fracture in Older Adults , 2008, Calcified Tissue International.
[34] K. Rothman,et al. Using prescription claims data for drugs available over‐the‐counter (OTC) , 2007, Pharmacoepidemiology and drug safety.
[35] Yu-Xiao Yang,et al. Long-term proton pump inhibitor therapy and risk of hip fracture. , 2006, JAMA.
[36] L. Fisher,et al. Perioperative acute upper gastrointestinal haemorrhage in older patients with hip fracture: incidence, risk factors and prevention , 2006, Alimentary pharmacology & therapeutics.
[37] A. Murray,et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. , 2005, The American journal of medicine.
[38] E. Bini,et al. Endoscopic treatment compared with medical therapy for the prevention of recurrent ulcer hemorrhage in patients with adherent clots. , 2003, Gastrointestinal endoscopy.
[39] K. Abe,et al. Effect of omeprazole, an inhibitor of H+, K+-ATPase, on bone resorption in humans , 1993, Calcified Tissue International.
[40] E. Savarino,et al. The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. , 2017, European journal of internal medicine.
[41] J. Zwerina,et al. Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study , 2015, Osteoporosis International.
[42] Y. Huang,et al. Proton-pump inhibitors and risk of fractures: an update meta-analysis , 2015, Osteoporosis International.
[43] MS Sandeep Vijan MD,et al. Defining Appropriate Use of Proton-Pump Inhibitors Among Medical Inpatients , 2015, Journal of General Internal Medicine.
[44] P. Eiken,et al. Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients—a nationwide register-based open cohort study , 2012, Osteoporosis International.
[45] C. Cooper,et al. Osteoporosis: trends in epidemiology, pathogenesis and treatment , 2006 .
[46] F. Rengo,et al. Drug use by the elderly in general practice: effects on upper gastrointestinal symptoms , 2005, European Journal of Clinical Pharmacology.
[47] R. Poon,et al. Risk factors for rebleeding and death from peptic ulcer in the very elderly , 1998, The British journal of surgery.